Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Related Research units
Abstract
The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.
Bibliographical data
| Original language | German |
|---|---|
| ISSN | 1471-2407 |
| DOIs | |
| Publication status | Published - 2010 |
| pubmed | 20712886 |
|---|
